Liquidia Reports $51.7M Q3 YUTREPIA Sales, Approaches Profitability

Liquidia Corporation, a biopharmaceutical company focused on treatments for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has reported significant financial progress in 2025 driven by the sales of its inhaled dry powder drug, YUTREPIA. The company achieved profitability in the third quarter with net product sales of $51.7 million and over 2,000 unique patient prescriptions, reflecting strong market adoption and enthusiasm from prescribers. YUTREPIA, approved by the FDA in May 2025, has contributed to an operating income of $1.7 million and a positive non-GAAP adjusted EBITDA of $10.1 million, marking a substantial improvement from prior losses. Liquidia also continues to develop additional therapies, including L606, an investigational twice-daily formulation of treprostinil, and maintains a promotion agreement for generic Treprostinil Injection. Despite these gains, the company faces challenges with profitability and financial strength, acknowledging the need for further financing if revenue growth does not sustain operational and developmental expenses. Liquidia's leadership will provide updates on their business at upcoming healthcare investment conferences, underscoring their commitment to advancing treatment options for respiratory and vascular diseases.